Agilent Technologies Reports Third-Quarter Fiscal Year 2018 Financial Results

Highlights:

Revenue of $1.20 billion, representing growth of 8 percent with core revenue growth of 6 percent⁽¹⁾
GAAP net income of $236 million, or $0.73 per share
Non-GAAP net income of $217 million, or $0.67 per share⁽²⁾, $0.05 above midpoint guidance of $0.62 per share, an increase of 14 percent from 2017
Fourth-quarter fiscal year revenue guidance of $1.24 billion to $1.26 billion, and non-GAAP earnings guidance of $0.72 to $0.74 per share⁽³⁾
Increasing fiscal year 2018 core revenue growth guidance to 6.1 percent at the midpoint from 5.5 percent⁽¹⁾ and fiscal year 2018 non-GAAP earnings guidance to $2.70 at the midpoint from $2.65⁽³⁾, an increase of 14 percent from 2017

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.20 billion for the third quarter ended July 31, 2018, up 8 percent year over year (up 6 percent on a core basis⁽¹⁾).

Third-quarter GAAP net income was $236 million, or $0.73 per share. Last year's third-quarter GAAP net income was $175 million, or $0.54 per share.

During the third quarter, Agilent had intangible amortization of $26 million, acquisition and integration costs of $7 million, transformational initiatives of $4 million, business exit and divestitures of $1 million, $20 million of step-up gain on our initial Lasergen investment, and $5 million in other costs. Excluding these items and a tax benefit of $42 million, Agilent reported third-quarter non-GAAP net income of $217 million, or $0.67 per share⁽²⁾, up 14 percent year over year.

"The Agilent team continues to capitalize on healthy end markets and delivered another strong quarter," said Mike McMullen, Agilent CEO and president. "Both earnings and revenue growth, led by China and the global pharma and chemical & energy end markets, exceeded expectations. In addition, we achieved our 14th consecutive quarter of improving our year-over-year core operating margins."

"We put our strong balance sheet to work creating value for shareholders and customers," McMullen continued. "We repurchased $243 million in shares, paid $48 million in dividends, and invested $430 million in M&A."

Financial Highlights

Third-quarter revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 6 percent year over year (up 5 percent on a core basis⁽¹⁾) with strength in the chemical & energy and pharma end markets. LSAG's operating margin for the quarter was 22.9 percent.

Third-quarter revenue of $426 million from the Agilent CrossLab Group (ACG) grew 10 percent year over year (up 8 percent on a core basis⁽¹⁾). Both services and consumables saw strong growth across all end markets and geographies. ACG's operating margin for the quarter was 23.8 percent.

Third-quarter revenue of $237 million from Agilent's Diagnostics and Genomics Group (DGG) grew 9 percent year over year (up 5 percent on a core basis⁽¹⁾). Strength in genomics and China led the results. DGG's operating margin for the quarter was 18.5 percent.

Agilent expects fourth-quarter 2018 revenue in the range of $1.24 billion to $1.26 billion. Fourth-quarter 2018 non-GAAP earnings are expected to be in the range of $0.72 to $0.74 per share⁽³⁾.

For fiscal year 2018, Agilent expects revenue of $4.86 billion to $4.88 billion and non-GAAP earnings of $2.69 to $2.71 per share⁽³⁾. The guidance is based on July 31, 2018 currency exchange rates.

Conference Call

Agilent's management will present more details about its third-quarter fiscal 2018 financial results on a conference call with investors today at 1:30 p.m. (Pacific Time). This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select "Q3 2018 Agilent Technologies Inc. Earnings Conference Call" in the "News & Events — Calendar of Events" section. The webcast will remain available on the company's website for 90 days.

Additional information regarding financial results can be found at www.investor.agilent.com by selecting "Financial Results" in the "Financial Information" section.

A telephone replay of the conference call will be available at approximately August 14, 2018 at 4:30 PM (Pacific Time) after the call and through August 22 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 3179138.

# # #

Financial Statements for Third-Quarter Fiscal 2018

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY


	Three Months Ended
	July 31,						Percent
		2018			2017		Inc/(Dec)

Net revenue	$	1,203		$	1,114		8	%

Costs and expenses:
Cost of products and services		542			518		5	%
Research and development		97			87		11	%
Selling, general and administrative		339			308		10	%
Total costs and expenses		978			913		7	%

Income from operations		225			201		12	%

Interest income		9			6		50	%
Interest expense		(18	)		(19	)	(5	%)
Other income (expense), net		26			5		—

Income before taxes		242			193		25	%

Provision for income taxes		6			18		(67	%)

Net income	$	236		$	175		35	%



Net income per share:
Basic	$	0.74		$	0.55
Diluted	$	0.73		$	0.54

Weighted average shares used in computing net income per share:
Basic		320			321
Diluted		324			326

Cash dividends declared per common share	$	0.149		$	0.132



The preliminary income statement is estimated based on our current information.

Page 1

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY


	Nine Months Ended
	July 31,						Percent
		2018			2017		Inc/(Dec)

Net revenue	$	3,620		$	3,283		10	%

Costs and expenses:
Cost of products and services		1,642			1,521		8	%
Research and development		281			250		12	%
Selling, general and administrative		1,018			904		13	%
Total costs and expenses		2,941			2,675		10	%

Income from operations		679			608		12	%

Interest income		28			15		87	%
Interest expense		(57	)		(59	)	(3	%)
Other income (expense), net		52			13		—

Income before taxes		702			577		22	%

Provision for income taxes		581			70		—

Net income	$	121		$	507		—



Net income per share:
Basic	$	0.38		$	1.57
Diluted	$	0.37		$	1.56

Weighted average shares used in computing net income per share:
Basic		322			322
Diluted		326			325

Cash dividends declared per common share	$	0.447		$	0.396



The preliminary income statement is estimated based on our current information.

Page 2

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(In millions)
(Unaudited)
PRELIMINARY


	Three Months Ended						Nine Months Ended
	July 31,						July 31,
		2018			2017			2018			2017

Net income	$	236		$	175		$	121		$	507

Other comprehensive income (loss), net of tax:

Unrealized gain (loss) on derivative instruments		6			(3	)		3			(3	)
Amounts reclassified into earnings related to derivative instruments		1			(1	)		4			(2	)
Foreign currency translation		(39	)		57			(13	)		61
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss		8			8			21			34
Change in net prior service benefit		(1	)		(1	)		(4	)		(4	)
Other comprehensive income (loss)		(25	)		60			11			86

Total comprehensive income	$	211		$	235		$	132		$	593


The preliminary statement of comprehensive income is estimated based on our current information.

Page 3

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share amounts)
(Unaudited)
PRELIMINARY


			July 31,			October 31,
				2018			2017
ASSETS

Current assets:
	Cash and cash equivalents		$	2,131		$	2,678
	Accounts receivable, net			733			724
	Inventory			623			575
	Other current assets			180			192
	Total current assets			3,667			4,169

Property, plant and equipment, net				801			757
Goodwill and other intangible assets, net				3,448			2,968
Long-term investments				70			138
Other assets				363			394
	Total assets		$	8,349		$	8,426

LIABILITIES AND EQUITY

Current liabilities:
	Accounts payable		$	273		$	305
	Employee compensation and benefits			251			276
	Deferred revenue			328			291
	Short-term debt			—			210
	Other accrued liabilities			162			181
	Total current liabilities			1,014			1,263

Long-term debt				1,799			1,801
Retirement and post-retirement benefits				218			234
Other long-term liabilities				750			293
	Total liabilities			3,781			3,591

Total Equity:
	Stockholders' equity:
	Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding			—			—
	Common stock; $0.01 par value, 2 billion shares authorized; 319 million shares at July 31, 2018 and 322 million shares at October 31, 2017, issued			3			3
	Additional paid-in-capital			5,312			5,300
	Accumulated deficit			(416	)		(126	)
	Accumulated other comprehensive loss			(335	)		(346	)
	Total stockholders' equity			4,564			4,831
	Non-controlling interest			4			4
	Total equity			4,568			4,835
		Total liabilities and equity	$	8,349		$	8,426



The preliminary balance sheet is estimated based on our current information.

Page 4

AGILENT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY


			Three Months			Three Months			Nine Months			Nine Months
			Ended			Ended			Ended			Ended
			July 31,			July 31,			July 31,			July 31,
				2018			2017			2018			2017
Cash flows from operating activities:
	Net income		$	236		$	175		$	121		$	507

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Depreciation and amortization			53			51			154			160
	Share-based compensation			13			13			56			48
	Excess and obsolete inventory related charges			5			4			22			19
	Gain on step acquisition of Lasergen			(20	)		—			(20	)		—
	Other non-cash expenses, net			5			3			7			5
	Changes in assets and liabilities:
		Accounts receivable, net		12			19			(9	)		(29	)
		Inventory		(32	)		(17	)		(66	)		(46	)
		Accounts payable		5			5			(9	)		11
		Employee compensation and benefits		(17	)		(18	)		(24	)		(11	)
		Change in assets and liabilities due to Tax Act		—			—			533			—
		Other assets and liabilities		(63	)		(7	)		(50	)		(63	)
Net cash provided by operating activities ^(a)				197			228			715			601

Cash flows from investing activities:
	Investments in property, plant and equipment			(33	)		(43	)		(141	)		(118	)
	Payment to acquire cost method investments			(10	)		—			(11	)		—
	Proceeds from divestitures			—			—			—			1
	Change in restricted cash and cash equivalents, net			—			—			1			—
	Payment in exchange for convertible note			—			(1	)		(2	)		(1	)
	Acquisition of businesses and intangible assets, net of cash acquired			(430	)		(57	)		(437	)		(127	)
Net cash used in investing activities				(473	)		(101	)		(590	)		(245	)

Cash flows from financing activities:
	Issuance of common stock under employee stock plans			17			32			53			58
	Payment of taxes related to net share settlement of equity awards			—			—			(29	)		(13	)
	Payment of dividends			(48	)		(42	)		(144	)		(127	)
	Proceeds from revolving credit facility			127			115			483			343
	Repayment of debt and revolving credit facility			(442	)		(76	)		(693	)		(163	)
	Treasury stock repurchases			(243	)		—			(336	)		(194	)
Net cash provided by (used) in financing activities				(589	)		29			(666	)		(96	)

Effect of exchange rate movements				(15	)		18			(6	)		14

Net increase (decrease) in cash and cash equivalents				(880	)		174			(547	)		274

Cash and cash equivalents at beginning of period				3,011			2,389			2,678			2,289

Cash and cash equivalents at end of period			$	2,131		$	2,563		$	2,131		$	2,563

	^(a) Cash payments included in operating activities:
		Income tax payments (refunds), net	$	38		$	15		$	86		$	56
		Interest payments	$	25		$	29		$	68		$	69



The preliminary cash flow is estimated based on our current information.


Page 5

AGILENT TECHNOLOGIES, INC.
NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS
(In millions, except per share amounts)
(Unaudited)
PRELIMINARY

			Three Months Ended												Nine Months Ended
			July 31,												July 31,
				2018		Diluted EPS				2017		Diluted EPS				2018		Diluted EPS				2017		Diluted EPS

GAAP net income			$	236		$	0.73		$	175		$	0.54		$	121		$	0.37		$	507		$	1.56
	Non-GAAP adjustments:
		Intangible amortization		26			0.08			27			0.08			76			0.23			89			0.27
		Business exit and divestiture costs		1			—			—			—			9			0.03			—			—
		Transformational initiatives		4			0.01			3			0.01			14			0.04			5			0.02
		Acquisition and integration costs		7			0.02			4			0.01			14			0.04			27			0.08
		Pension settlement gain		—			—			—			—			(5	)		(0.02	)		(32	)		(0.10	)
		Gain on step acquisition of Lasergen		(20	)		(0.06	)		—			—			(20	)		(0.06	)		—			—
		NASD site costs		2			0.01			—			—			6			0.02			—			—
		Special compliance costs		1			—			—			—			3			0.01			—			—
		Other		2			0.01			1			—			(12	)		(0.03	)		5			0.02
		Adjustment for Tax Reform		—			—			—			—			533			1.63			—			—
		Adjustment for taxes ^(a)		(42	)		(0.13	)		(19	)		(0.05	)		(94	)		(0.28	)		(51	)		(0.16	)
Non-GAAP net income			$	217		$	0.67		$	191		$	0.59		$	645		$	1.98		$	550		$	1.69


^(a) The adjustment for taxes excludes tax benefits that management believes are not directly related to on-going operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. For the three and nine months ended July 31, 2018, management uses a non-GAAP effective tax rate of 18.0%. In the same periods last year, management used a non-GAAP effective tax rate of 16.2% and 18.0%, respectively.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, pension settlement gain, gain on step acquisition of Lasergen, NASD site costs, special compliance costs, and adjustment for Tax Reform.

	Business exit and divestiture costs include costs associated with business divestitures.

	Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing due to new tariffs and tariff remediation actions, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.

	Acquisition and Integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

	Pension settlement gain resulted from transfer of the substitutional portion of our Japanese pension plan to the government.

	Gain on step acquisition of Lasergen resulted from the measurement at fair value of our equity interest held at the date of business combination.

	NASD site costs include all the costs related to the expansion of our manufacturing of nucleic acid active pharmaceutical ingredients incurred prior to the commencement of commercial manufacturing.

	Special compliance costs include costs associated with transforming our processes to implement new regulations such as the EU's General Data Protection Regulation (GDPR), revenue recognition and certain tax reporting requirements.

	Other includes certain legal costs and settlements in addition to other miscellaneous adjustments.

	Adjustment for Tax Reform primarily consists of an estimated provision of $480 million for U.S. transition tax and correlative items on deemed repatriated earnings of non-U.S. subsidiaries and an estimated provision of $53 million associated with the decrease in the U.S. corporate tax rate from 35% to 21% and its impact on our U.S. deferred tax assets and liabilities. The taxes payable associated with the transition tax, net of tax attributes, on deemed repatriation of foreign earnings is approximately $440 million, payable over 8 years. The final impact of Tax Reform may differ materially from these estimates, due to, among other things, changes in interpretations, analysis and assumptions made, additional guidance that may be issued, and actions that we may undertake.


Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.

Page 6

AGILENT TECHNOLOGIES, INC.
SEGMENT INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY

Life Sciences and Applied Markets Group
	Q3'18			Q3'17
Revenue	$	540		$	510
Gross Margin, %		61.3	%		59.9	%
Income from Operations	$	123		$	109
Operating margin, %		22.9	%		21.4	%


Diagnostics and Genomics Group
	Q3'18			Q3'17
Revenue	$	237		$	218
Gross Margin, %		57.0	%		52.9	%
Income from Operations	$	44		$	37
Operating margin, %		18.5	%		17.1	%


Agilent CrossLab Group
	Q3'18			Q3'17
Revenue	$	426		$	386
Gross Margin, %		50.6	%		49.9	%
Income from Operations	$	102		$	90
Operating margin, %		23.8	%		23.4	%






Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to amortization of intangibles, business exit and divestiture costs, transformational initiatives, acquisition and integration costs, NASD site costs, and special compliance costs.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

Page 7

AGILENT TECHNOLOGIES, INC.
RECONCILIATIONS OF REVENUE BY SEGMENT EXCLUDING
ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)
(in millions)
(Unaudited)
PRELIMINARY

	Year-over-Year

	GAAP
					Year-over-Year
GAAP Revenue by Segment	Q3'18		Q3'17		% Change

Life Sciences and Applied Markets Group	$	540	$	510	6	%

Diagnostics and Genomics Group		237		218	9	%

Agilent CrossLab Group		426		386	10	%

Agilent	$	1,203	$	1,114	8	%




	Non-GAAP (excluding Acquisitions & Divestitures)						Year-over-Year at Constant Currency ^(a)
					Year-over-Year		Year-over-Year		Percentage Point Impact from Currency	Current Quarter Currency Impact^(b)
Non GAAP Revenue by Segment	Q3'18		Q3'17		% Change		% Change

Life Sciences and Applied Markets Group	$	538	$	508	6	%	5	%	1 ppt	$	7

Diagnostics and Genomics Group		232		218	7	%	5	%	2 ppts		4

Agilent CrossLab Group		426		386	10	%	8	%	2 ppts		7

Agilent (Core)	$	1,196	$	1,112	8	%	6	%	2 ppts	$	18



We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

^(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter, and then using those revised values to calculate the year-over-year percentage change.

^(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

Page 8

Download Financial Statements for Third-Quarter Fiscal 2018

Financial Tables (165KB)

Newsroom

Press Release